D.E. Shaw & Co
ANVS icon

D.E. Shaw & Co’s Annovis Bio ANVS Stock Holding History

D.E. Shaw & Co’s Portfolio ANVS Stock Details ANVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-18,789
Closed -$28.2K – 4326
2025
Q1 		$28.2K Buy
+18,789
New +$57.5K ﹤0.01% 4089
2024
Q4 		– Sell
-24,410
Closed -$197K – 4384
2024
Q3 		$197K Buy
+24,410
New +$229K ﹤0.01% 4164
2021
Q4 		– Sell
-7,908
Closed -$251K – 5370
2021
Q3 		$251K Buy
+7,908
New +$455K ﹤0.01% 4456

Other funds holding ANVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
WFAG
Wescott Financial Advisory Group Philadelphia, Pennsylvania $1.14B AUM 16.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co's ANVS Position: Q2 2025 in Review

D.E. Shaw & Co sold out of Annovis Bio (ANVS) in Q2 2025, closing a stake of 18,789 shares — an estimated $28.2K sold.

D.E. Shaw & Co first reported a position in ANVS in Q3 2021 and held it in 3 quarters. The position peaked at $251K in Q3 2021. 42 funds tracked by Wall St. Rank hold ANVS as of Q2 2025.

  • D.E. Shaw & Co reported no remaining Annovis Bio position as of Q2 2025 after selling out during the quarter.
  • D.E. Shaw & Co sold 18,789 Annovis Bio shares in Q2 2025, an estimated $28.2K.
  • D.E. Shaw & Co first reported a position in Annovis Bio in Q3 2021 and held it in 3 quarters.
  • D.E. Shaw & Co's Annovis Bio position peaked at $251K in Q3 2021.
  • 42 funds tracked by Wall St. Rank held Annovis Bio as of Q2 2025.

Based on D.E. Shaw & Co's 13F filing for Q2 2025, filed 14 Aug 2025.